Based on cancer stem cell theory, cancer stemness is enhanced in surviving tumor cells, which are referred to as initiating cells, after cisplatin chemotherapy, and HSP90 inhibitors improve the sensitivity of bladder cancer initiating cells to cisplatin chemotherapy [39]. Here, HSP90AB1 is linked to urinary bladder cancer.